Emerging pharmacotherapies, such as GLP-1 receptor agonists (e.g., liraglutide) and SGLT2 inhibitors (e.g., empagliflozin), offer promising adjunctive treatments by promoting weight loss, enhancing satiety, reducing hepatic glucose production and increasing urinary glucose excretion, thereby addressing multiple facets of metabolic syndrome simultaneously [23]. Here, SLC5A2 is linked to metabolic syndrome.